CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES

我们假设，将患者的自体肿瘤细胞与卡介苗混合后接种疫苗，将在从疫苗部位流出的淋巴结内诱导T细胞免疫反应。为了验证这一假设，晚期恶性肿瘤患者接种了经照射的自身肿瘤细胞混合卡介苗皮下接种，一周后切除引流淋巴结进行体外激活。经过一段时间的活化后，将这些细胞连同IL-2一起重新输注到患者体内。迄今为止，在11名黑色素瘤患者和12名肾细胞癌患者中，我们已经记录了产生高度特异性的疫苗引发的T淋巴细胞对自体肿瘤反应的能力。在这些患者中，一些人在过继移植细胞后，肿瘤明显消退。我们在晚期肾细胞癌患者中继续进行这项研究，以确定T细胞的体外免疫功能与体内肿瘤反应性之间的关系。

We hypothesize that the vaccination of patients with autologous tumor cells admixed with BCG will induce a T cell immune response within draining lymph nodes from the site of the vaccine. To test this hypothesis, patients with advanced malignancies are vaccinated with irradiated autologus tumor cells admixed with BCG intradermaly and the draining lymph nodes removed one week later for ex vivo activation. After a period of activation, the cells are reinfused into the patients along with the administration of IL-2. To date, in 11 melanoma patients and 12 renal cell cancer patients we have documented the ability to generate highly specific vaccine-primed T lymphocytes reactive to autologous tumor. Significant tumor regression has been noted in some of these patients after adoptive transfer of the cells. We are continuing this study in advanced renal cell cancer patients to correlate in vitro immunological function of T cells with in vivo tumor reactivity.